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Conclusions: Preliminary results showed acute breast edema 
in 1 out of 4 breast cancer patients undergoing irradiation 
after any surgical treatment and is more common after neo-
adjuvant chemotherapy. Updated results with a larger sample 
size and longer follow-up, as well as data on quality of life, 
pain and cosmetic results in association with acute and 
chronic breast edema will be presented at the ESTRO 
conference. 
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Purpose/Objective: First, to assess the long-term outcome of 
a retrospective cohort of 187 breast cancer (BC) patients who 
received pre-mastectomy radiotherapy. Second, to analyze 
predictive factors for disease-free survival (DFS) and overall 
survival (OS). 
Materials and Methods: From 1970 to 1984, 187 consecutive 
BC patients were treated with pre-mastectomy 
hypofractionated radiotherapy on whole breast, 
supraclavicular fossa, axilla +/- ipsilateral internal mammary 
lymph nodes (45-55Gy/18 fractions/34 days, IQR [31-36]). 
None received neo-adjuvant systemic treatment. Histology 
was centrally reviewed for the purpose of the present study. 
Local recurrence (LR), DFS and OS were estimated using the 
Kaplan-Meier method, survival comparisons by log-rank test, 
and prognostic factors by multivariable Cox models stratified 
on age. 
Results: Most patients (88%) had an early stage BC, 
characterized at that time by rapid growth (clinical doubling 
time < 6 months), and 122 (65%) were clinically N+. BCs were 
mainly T2 (91%) with some T3 (1%) and T4 (8%) tumours. 
Among the 166 reanalyzed biopsies 22% were triple negative, 
17% HER2 positive and 31% grade III. The median age was 49 
years [43-60]. ypT0, defined as the absence of residual 
invasive disease in the mastectomy specimen, was achieved 
in 26 patients (14%) and in 29% of triple negative patients. 
Pathological complete response defined as ypT0 + ypN0 was 
achieved in 18 patients (10%). The rate of ypT0 was linked to 
ypN0 status (OR=3.5, IC95% [1.2-10], p=0.02) and borderline 
to triple negative tumor status (OR=2.4, [0.9-6.7], p=0.08). 
The postoperative complication rate was 20% (37/187) with 
4.3% of skin necrosis (8/187). Adjuvant chemotherapy was 
delivered to 31% of patients. 
With a median follow-up of 32 years [23-35], the 10- and 25-
year rates were 9% [5% -15%] and 11% [7%-18%] for LR, 47% 
[40%-54%] and 30% [24%-37%] for DFS, 55% [47%-62%] and 30% 
[23%-37%] for OS. ypT0 was neither significantly related to 
LR, nor to DFS or OS. Triple negative patients experienced 
significantly more LR (HR=4.9 [1.2-21], adjusted on pN 
status). In the multivariable analysis on OS, pN status (HR= 
1.69, [1.28-2.22], p=0.0002), triple negative status (HR=1.80, 
[1.00-3.26], p=0.05) and HER2 status after 50 years (HR=3.46, 
[1.80-6.66], p=0.0002; test of interaction before 50 vs. after 
50, p=0.01) had significant prognostic impact. 
Conclusions: Long-term local control achieved by 
preoperative hypofractionated radiotherapy followed by 
radical mastectomy was excellent, with an acceptable rate of 
postoperative complications. These results might help 
identify subpopulations able to benefit from preoperative 
radiation therapy.  
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Purpose/Objective: Radiotherapy of breast cancer patients 
with a tissue expander / implant (E/I) is a challenging 
intervention due to possible complications. Capsular fibrosis 
is one the most important side effects. It may lead to 
removal or exchange of the E/I (reconstruction failure). 
Other complications such as breast / chest wall pain and 
lymph edema can also considerably decrease the quality of 
life (QoL) of these women. The main purpose of this analysis 
was to assess the incidence and severity of acute and late 
local toxicity as well as the rate of reconstruction failure. An 
additional aim was to examine QoL and patient satisfaction 
with the breast reconstruction. 
Materials and Methods: We identified 58 women (age 33 – 74 
at the time of radiotherapy) with E/I who were treated with 
radiotherapy due to breast cancer at our institution between 
February 2000 and December 2013. Among them, 52 had a 
mastectomy with primary breast reconstruction and 6 already 
had breast implants for cosmetic reasons before first 
diagnosis of breast cancer. The total radiotherapy dose was 
between 50 and 60.4 Gy (single dose 1.8 or 2 Gy). Acute and 
late side effects were scored according to CTCAE v.4.03. To 
investigate QoL and satisfaction with the breast 
reconstruction the EORTC questionnaires QLQ-C30 / QLQ-
BR23 as well as three additional questions were used. Median 
follow up was 2.3 years. 
Results: The most common acute side effects were radiation 
dermatitis (91.4 %), skin hyperpigmentation (46.6 %), breast / 
chest wall pain (24.2 %) and lymph edema (13.7 % in the 
breast/chest wall, 6.8% in the arm). As late complications, 
we observed most frequently skin hyperpigmentation (34.5 
%), breast / chest wall pain (22.4 %) and lymph edema (6.8 % 
in the breast / chest wall, 18.9 % in the arm). Severe 
capsular fibrosis (Baker grade III and IV) occurred in 25.1 % of 
the women. Reconstruction failure was detected in 25.9 % 
and only during the first 4.6 years after radiotherapy. 
Compared to EORTC reference values for breast cancer 
patients, our patients showed similar outcome for QoL. Most 
women were well (55.0 %) or moderately (35.0 %) satisfied 
with their breast reconstruction and 75.0 % would choose the 
same way of breast reconstruction again. 
Conclusions: There are no established risk factors for 
complications in patients with E/I after radiation therapy. 
Thus, women suffering from breast cancer have to be well 
educated about potential risks by primary implant-based 
breast reconstruction and adjuvant radiotherapy. It is very 
important that a multidisciplinary team together with the 
patient finds the best individual approach for cancer 
treatment and breast reconstruction when mastectomy and 
radiotherapy might be necessary.  
